RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56

Benzinga Newsdesk www.benzinga.com Negative 93.9%

Neg 93.9% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.